KLOW (Blend)

Half of This Blend Is Small Enough to Share a Route

UKPWritten and published by UK Peptides4 min readUpdated 5 cited sources

The short answer

Two of KLOW's four components are tripeptides, and one of them (KPV) is a demonstrated substrate of the di- and tripeptide transporter PepT1. Whether the other tripeptide competes for the same carrier is an obvious question with no published answer.

Key facts

Tripeptides in the blend
2 of 4 (KPV and GHK)
KPV sequence
Lys-Pro-Val
GHK sequence
Gly-His-Lys
Transporter
PepT1, gene SLC15A1
KPV as PepT1 substrate
Demonstrated by competition, labelled uptake and knockout
GHK as PepT1 substrate
Not established in the literature reviewed here
PepT1 charge preference
Neutral and acidic peptides at physiological pH
Both blend tripeptides
Basic

Why size sorts this blend into two halves

PepT1 carries di- and tripeptides. That is its defined substrate range, and it is a strict one: the transporter does not carry free amino acids and it does not carry peptides of four residues or more. Applied to KLOW, that draws a line straight through the middle of the vial. KPV is three residues and GHK is three residues, so both fall inside the range. TB-500 as supplied is full-length thymosin beta-4 at 43 residues and BPC-157 is fifteen residues, so both fall well outside it. Whatever route the larger two take, it is not this one.

What is established for KPV

More than for most compounds in this library. Dalmasso and colleagues demonstrated PepT1-mediated uptake of KPV using unlabelled KPV as a competitor against a radiolabelled PepT1 substrate and tritiated KPV to determine its own transport kinetics, in human intestinal epithelial and T-cell lines. Viennois and colleagues then showed that in PepT1-knockout mice, KPV produced none of the effect it produced in wild-type animals. Competition, direct labelled uptake and a genetic knockout is a complete set, and it makes KPV's status as a PepT1 substrate about as well supported as such things get.

Research material referenced

KLOW 80mg, third-party HPLC tested

Buy KLOW · £79.99

What is not established for GHK

Whether it is a substrate at all. GHK is Gly-His-Lys, a tripeptide, and PepT1 has broad specificity. It recognises general structural features rather than particular sequences, which is why it carries thousands of possible di- and tripeptides and a range of peptidomimetic drugs never designed for it. On that basis GHK is a reasonable candidate. But candidacy is not demonstration, no work reviewed here tests it, and the copper complex adds a complication: GHK-Cu is not GHK, and a chelated cupric ion changes the molecule's size, charge and shape in ways a transporter would notice.

The charge point, which cuts against both

Steel and colleagues characterised PepT1's stoichiometry and pH dependence and found that at physiological external pH, around 5.5 to 6.0 at the brush border. The transporter prefers neutral and acidic peptides. Basic dipeptides had their transport maxima shifted to higher pH, which the authors suggest may involve titration of a side chain on the transporter itself. KPV carries a lysine and GHK carries both a histidine and a lysine, so both are basic peptides and both sit in the class the transporter handles least favourably at the pH where it normally operates. That does not make KPV a non-substrate (it demonstrably is one) but it does mean the two tripeptides here are competing, if they compete at all, in the same disfavoured charge category.

Why the question is worth asking of a blend specifically

Two compounds administered separately do not compete for a transporter in any meaningful sense unless they happen to be present together. A co-formulation like the KLOW blend guarantees they are. If both tripeptides in this vial are PepT1 substrates, then the amount of either that crosses depends on how much of the other is present, which makes the blend's behaviour a function of its ratio in a way that has nothing to do with pharmacology at the target and everything to do with a shared carrier. That is the most concrete mechanistic reason to want the per-component split stated, and it is a question no work on this combination has addressed because no work on this combination exists.

What is and is not being claimed

That KPV is a PepT1 substrate is published and well controlled. That GHK is a tripeptide is a structural fact. That PepT1 prefers neutral and acidic peptides at physiological pH is published. Everything joining those together into a statement about what happens in a vial containing both is a question, written here as a question. No published work addresses this combination in any respect, and nothing here describes what any compound does in a person. All four components are supplied for laboratory research only.

Quick reference

ComponentResiduesIn PepT1's substrate rangeEstablished as a substrate
KPV3YesYes (competition, labelled uptake, knockout)
GHK-Cu3 plus a chelated copper ionBy size, yesNot established
TB-500 (thymosin beta-4)43NoNo
BPC-15715NoNo

Frequently asked questions

Does this mean the components interfere with each other?

It means there is a specific mechanism by which two of them could, which nobody has tested. Stating an untested possibility as a finding would be exactly the error this library exists to avoid.

Would the copper stop GHK-Cu being transported?

It might. A chelated metal ion changes the molecule's dimensions and charge distribution substantially, and transporters are sensitive to both. Whether GHK-Cu, free GHK, or neither is a substrate is unresolved in the literature reviewed here.

Is PepT1 relevant if the blend is not taken orally?

PepT1 is best characterised in intestinal epithelium, which is why oral exposure is where it matters most. Nothing here concerns administration of any kind. This is a statement about a transporter's substrate range and about which molecules fall inside it.

Why does the charge preference matter?

Because it sets which peptides the transporter handles well at the pH it normally works at. Two basic tripeptides in one vial are competing, if at all, within the category the transporter is least efficient at, which would make any competition between them more consequential, not less.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More KLOW (Blend) articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.